Home › Funds › SEGALL BRYANT & HAMILL, LLC › HALO

SEGALL BRYANT & HAMILL, LLC position in HALO

HALOZYME THERAPEUTICS INC · Health Care

SEGALL BRYANT & HAMILL, LLC reported holding 313,010 shares of HALO (HALOZYME THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$34.6M, representing 0.46% of its reported portfolio and ranking #49 among its reported holdings. SEGALL BRYANT & HAMILL, LLC has disclosed HALO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)313.01K sh
Reported value held$34.56M
Portfolio Weight0.46%
First reportedQ3 2023
Last changeReduce
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How SEGALL BRYANT & HAMILL, LLC's HALO position evolved

SEGALL BRYANT & HAMILL, LLC first disclosed a stake in HALO in Q3 2023 at 218,405 shares (US$8.3M). The position peaked in Q3 2026 at 313,010 shares, worth US$34.6M. Across 13 filings, SEGALL BRYANT & HAMILL, LLC increased the stake 6 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 313,010 shares valued at US$34.6M — a reduction of -4,914 shares quarter over quarter.. Notable position changes include a 30% trim in Q3 2025 (shares fell 8% over the following quarter), a 42% increase in Q4 2025 (shares fell 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 218.41K $8.34M New
Q4 2023 242.47K $8.96M Add
Q1 2024 269.96K $10.98M Add
Q2 2024 305.32K $15.99M Add
Q3 2024 355.18K $20.33M Add
Q4 2024 353.10K $16.88M Reduce
Q1 2025 343.17K $21.90M Reduce
Q2 2025 310.83K $16.17M Reduce
Q3 2025 216.57K $15.88M Reduce
Q4 2025 307.22K $20.68M Add
Q1 2026 298.06K $19.26M Reduce
Q2 2026 317.92K $24.88M Add
Q3 2026 313.01K $34.56M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About HALO and 13F data

HALO (HALOZYME THERAPEUTICS INC) is a Health Care company. 45 other funds we track also report a position in HALO — the largest reported positions include CONGRESS ASSET MANAGEMENT CO (US$251.9M), SNYDER CAPITAL MANAGEMENT L P (US$244.3M), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (US$178.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding HALO

All HALO fund holders →

FAQ

How long has SEGALL BRYANT & HAMILL, LLC held HALO?

SEGALL BRYANT & HAMILL, LLC has disclosed HALO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is SEGALL BRYANT & HAMILL, LLC's current position in HALO?

As of Q3 2026, SEGALL BRYANT & HAMILL, LLC holds 313.01K shares of HALO (HALOZYME THERAPEUTICS INC), valued at $34.56M, representing 0.46% of its reported portfolio and ranking #49.

Has SEGALL BRYANT & HAMILL, LLC been buying or selling HALO?

In the latest 13F filing (Q3 2026), SEGALL BRYANT & HAMILL, LLC reduced its position in HALO. The position peaked in Q3 2026 at 313.01K shares.

Which other funds hold HALO?

Other major institutional holders of HALO include CONGRESS ASSET MANAGEMENT CO, SNYDER CAPITAL MANAGEMENT L P, WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC, among 45 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.